<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10021">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02035605</url>
  </required_header>
  <id_info>
    <org_study_id>ALN-AT3SC-001</org_study_id>
    <nct_id>NCT02035605</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients</brief_title>
  <official_title>A Phase 1 Single-ascending and Multiple-ascending Dose, Safety, Tolerability and Pharmacokinetics Study of Subcutaneously Administered ALN-AT3SC in Healthy Adult Volunteers and Hemophilia A or B Patients (Moderate or Severe Hemophilia)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alnylam Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alnylam Pharmaceuticals</source>
  <oversight_info>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of
      ALN-AT3SC in healthy volunteers and Hemophilia A or B patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">November 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The safety of ALN-AT3SC evaluated by the proportion of subjects experiencing adverse events (AEs), serious adverse events (SAEs), dose-limiting toxicities (DLTs), and AEs leading to study drug discontinuation.</measure>
    <time_frame>Part A (SAD phase): through day 56; Part B (MAD) phase: through Day 70</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>The pharmacokinetics (PK) of ALN-AT3SC as characterized by plasma PK profiles and urine samples.</measure>
    <time_frame>Part A (SAD) phase: through day 56; Part B (MAD) phase: through Day 70</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The pharmacodynamic (PD) effect of ALN-AT3SC, evaluated by Plasma AT levels.</measure>
    <time_frame>Part A (SAD) phase: through day 56; Part B (MAD) phase: through Day 70</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The pharmacodynamic (PD) effect of ALN-AT3SC, evaluated by Plasma TG.</measure>
    <time_frame>Part A (SAD) phase: through day 56; Part B (MAD) phase: through Day 70</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Hemophilia A</condition>
  <condition>Hemophilia B</condition>
  <arm_group>
    <arm_group_label>ALN-AT3SC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sterile Normal Saline (0.9% NaCl)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALN-AT3SC</intervention_name>
    <description>Ascending doses of ALN-AT3SC by subcutaneous (sc) injection</description>
    <arm_group_label>ALN-AT3SC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sterile Normal Saline (0.9% NaCl)</intervention_name>
    <description>Calculated volume to match active comparator</description>
    <arm_group_label>Sterile Normal Saline (0.9% NaCl)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Part A (SAD phase) inclusion:

          -  Healthy adult males aged 18 to 40 years inclusive at Screening.

          -  Subjects with adequate complete blood counts and liver function tests.

          -  Willing to provide written informed consent and willing to comply with study
             requirements.

        Part B (MAD phase) inclusion:

          -  Adult male hemophilia patients aged 18 to 65 years inclusive at Screening.

          -  Patients with adequate complete blood counts and liver function tests.

          -  Patients with moderate or severe, clinically stable hemophilia A or B (Factor VIII or
             Factor IX ≤5%).

          -  Willing to provide written informed consent and willing to comply with study
             requirements

        Exclusion Criteria:

        Part A (SAD phase) exclusion:

          -  Subjects with a personal history and/or family history of venous thromboembolism
             (VTE)

          -  Subjects with a known co-existing thrombophilic disorder

          -  Subjects with a history of multiple drug allergies or history of allergic reaction to
             an oligonucleotide or GalNAc.

          -  Subjects with a history of serious mental illness that includes, but is not limited
             to schizophrenia, bipolar disorder, severe depression requiring hospitalization or
             pharmacological intervention.

          -  Subjects who have a clinically relevant history or presence of cardiovascular,
             respiratory, gastrointestinal, renal, hematological, lymphatic, neurological,
             musculoskeletal, genitourinary, immunological including osteoarthritis and other
             inflammatory diseases, dermatological including rash, eczema, dermatitis, or
             connective tissue diseases or disorders.

        Part B (MAD phase) exclusion:

          -  Patients with a history of serious mental illness, that includes, but is not limited
             to schizophrenia, bipolar disorder, severe depression requiring hospitalization or
             pharmacological intervention.

          -  Patients who have a clinically relevant history or presence of cardiovascular,
             respiratory, gastrointestinal, renal, neurological, inflammatory or other diseases
             that in the judgment of the investigator precludes their participation in the study.

          -  Patients with a known co-existing thrombophilic disorder

          -  Patients with a history of multiple drug allergies or history of allergic reaction to
             an oligonucleotide or GalNAc.

          -  Patients who are known to be HIV positive and have a CD4 count &lt;400 cells/μL
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benny Sorensen, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Alnylam Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alnylam Clinical Trials Hotline Call for Complete Site List</last_name>
    <phone>617-575-7400</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alnylam Clinical Trials Hotline Call for Complete Site List</last_name>
    <phone>1-866-330-0326</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 13, 2014</lastchanged_date>
  <firstreceived_date>January 13, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemophilia B</mesh_term>
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
